{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:53:27Z","timestamp":1794113607601,"version":"4.8.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Although relatively rare, acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. AML is associated with poor 5-year overall survival and prompt treatment is critical. Classifying AML based on World Health Organization criteria is important for determining prognosis and applying a risk-adapted treatment approach. Throughout therapy, patients require comprehensive supportive care measures with blood product transfusions, antimicrobial treatment, and frequent monitoring for chemotherapy-related complications. This article provides an overview of AML and its treatments. Clinicians in all specialties must be able to recognize the early signs of AML and ensure their patients seek appropriate expert medical care with a hematologist\/oncologist.<\/jats:p>","DOI":"10.1097\/01.jaa.0000995680.52352.b5","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T23:00:27Z","timestamp":1703199627000},"page":"34-39","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Acute myeloid leukemia"],"prefix":"10.1097","volume":"37","author":[{"given":"Michelle","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"1","key":"R1-20250605","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","article-title":"Molecular biomarkers in acute myeloid leukemia","volume":"31","author":"Prada-Arismendy","year":"2017","journal-title":"Blood Rev"},{"issue":"1","key":"R2-20250605","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"7","key":"R4-20250605","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"issue":"11","key":"R5-20250605","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"9","key":"R6-20250605","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"R7-20250605","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"R8-20250605","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.05.013","article-title":"Hypomethylating agents in the treatment of acute myeloid leukemia: a guide to optimal use","volume":"140","author":"Santini","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"R10-20250605","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1097\/HS9.0000000000000572","article-title":"Treatment for relapsed\/refractory acute myeloid leukemia","volume":"5","author":"Thol","year":"2021","journal-title":"Hemasphere"},{"issue":"27","key":"R11-20250605","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"R12-20250605","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","article-title":"CPX-351 (vyxeos) in AML","volume":"61","author":"Alfayez","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"10388","key":"R13-20250605","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"R14-20250605","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"R15-20250605","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"R16-20250605","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-021-01142-x","article-title":"Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial","volume":"14","author":"Ravandi","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"24","key":"R17-20250605","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"R18-20250605","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"R19-20250605","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"R20-20250605","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1007\/s00520-021-06119-7","article-title":"Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia","volume":"29","author":"Pelcovits","year":"2021","journal-title":"Support Care Cancer"},{"issue":"30","key":"R21-20250605","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"28","key":"R22-20250605","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"R23-20250605","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"R24-20250605","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3324\/haematol.2019.240754","article-title":"Potential targeting of FLT3 acute myeloid leukemia","volume":"106","author":"Ambinder","year":"2021","journal-title":"Haematologica"},{"issue":"13","key":"R25-20250605","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"issue":"7","key":"R26-20250605","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"issue":"1","key":"R27-20250605","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"issue":"9825","key":"R28-20250605","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"R29-20250605","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-018-1047-7","article-title":"Glasdegib: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"R30-20250605","first-page":"157","article-title":"HLA typing and its influence on organ transplantation","volume":"333","author":"Sheldon","year":"2006","journal-title":"Methods Mol Biol"},{"issue":"Pt 1","key":"R31-20250605","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1242\/jcs.03309","article-title":"Hedgehog signaling","volume":"120","author":"Varjosalo","year":"2007","journal-title":"J Cell Sci"},{"key":"R32-20250605","doi-asserted-by":"crossref","first-page":"e390010","DOI":"10.1200\/EDBK_390010","article-title":"Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia","volume":"43","author":"Dekker","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"R33-20250605","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.JAA.0000723908.23506.85","article-title":"Managing tumor lysis syndrome","volume":"34","author":"Greguska","year":"2021","journal-title":"JAAPA"},{"key":"R34-20250605","doi-asserted-by":"crossref","first-page":"9684909","DOI":"10.1155\/2017\/9684909","article-title":"Tumor lysis syndrome in patients with hematological malignancies","volume":"2017","author":"Belay","year":"2017","journal-title":"J Oncol"},{"issue":"4","key":"R35-20250605","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bjh.16278","article-title":"Emergencies in haematology: tumour lysis syndrome","volume":"188","author":"Durani","year":"2020","journal-title":"Br J Haematol"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000995680.52352.b5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:02:34Z","timestamp":1749153754000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000995680.52352.b5"}},"subtitle":["Current understanding and management"],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000995680.52352.b5","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}